| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Katarzyna Simonienko, Natalia Wygnał, Urszula Cwalina, Mikołaj Kwiatkowski, Agata Szulc, Napoleon Waszkiewic. The reasons for use of cannabinoids and stimulants in patients with schizophrenia. Psychiatria polska. vol 52. issue 2. 2018-11-19. PMID:29975366. |
the reasons for use of cannabinoids and stimulants in patients with schizophrenia. |
2018-11-19 |
2023-08-13 |
Not clear |
| G M Mandolini, M Lazzaretti, A Pigoni, L Oldani, G Delvecchio, P Brambill. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiology and psychiatric sciences. vol 27. issue 4. 2018-11-06. PMID:29789034. |
findings to date suggest that (a) cbd may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) cbd administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1a receptor agonism; (c) cbd may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of cbd still lack significant results in psychiatric disorders. |
2018-11-06 |
2023-08-13 |
Not clear |
| William E Fantegrossi, Catheryn D Wilson, Michael D Berquis. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug metabolism reviews. vol 50. issue 1. 2018-08-20. PMID:29385930. |
an association between marijuana use and schizophrenia has been noted for decades, and the recent emergence of high-efficacy synthetic cannabinoids (scbs) as drugs of abuse has lead to a growing number of clinical reports of persistent psychotic effects in users of these substances. |
2018-08-20 |
2023-08-13 |
Not clear |
| William E Fantegrossi, Catheryn D Wilson, Michael D Berquis. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug metabolism reviews. vol 50. issue 1. 2018-08-20. PMID:29385930. |
the mechanisms underlying scb-elicited pro-psychotic effects is unknown, but given the ubiquitous neuromodulatory functions of the endocannabinoid system, it seems likely that agonist actions at cannabinoid type-1 receptors (cb1rs) might modulate the functions of other neurotransmitter systems known to be involved in schizophrenia. |
2018-08-20 |
2023-08-13 |
Not clear |
| María Rodríguez-Muñoz, Pilar Sánchez-Blázquez, Luis F Callado, J Javier Meana, Javier Garzón-Niñ. Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational psychiatry. vol 7. issue 12. 2018-07-27. PMID:29249810. |
schizophrenia and depression, two poles of endocannabinoid system deregulation. |
2018-07-27 |
2023-08-13 |
human |
| María Rodríguez-Muñoz, Pilar Sánchez-Blázquez, Luis F Callado, J Javier Meana, Javier Garzón-Niñ. Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational psychiatry. vol 7. issue 12. 2018-07-27. PMID:29249810. |
thus, an altered endocannabinoid system may contribute to the pathophysiology of schizophrenia and depression by modifying the hint1-nr1 c1/gpcr ratio, thereby altering gpcr-nmdar cross-regulation. |
2018-07-27 |
2023-08-13 |
human |
| Christin Schifani, Sina Hafizi, Tania Da Silva, Jeremy Joseph Watts, M Saad Khan, Romina Mizrah. Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. International review of psychiatry (Abingdon, England). vol 29. issue 6. 2018-07-25. PMID:29219634. |
changes in several brain neurochemical systems and molecular mechanisms are implicated in the pathophysiology of schizophrenia and the psychosis spectrum, including the dopaminergic, γ-aminobutyric acid (gaba)-ergic, glutamatergic, endocannabinoid, and immunologic (i.e. |
2018-07-25 |
2023-08-13 |
human |
| Claudio D'Addario, Vincenzo Micale, Martina Di Bartolomeo, Tibor Stark, Mariangela Pucci, Alexandra Sulcova, Mariacarlotta Palazzo, Zuzana Babinska, Laura Cremaschi, Filippo Drago, A Carlo Altamura, Mauro Maccarrone, Bernardo Dell'Oss. A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophrenia research. vol 188. 2018-05-30. PMID:28108228. |
a preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of cnr1 promoter dna methylation in patients with schizophrenia. |
2018-05-30 |
2023-08-13 |
human |
| Gábor Nagy-Grócz, Ferenc Zádor, Szabolcs Dvorácskó, Zsuzsanna Bohár, Sándor Benyhe, Csaba Tömböly, Árpád Párdutz, László Vécse. Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine. International journal of molecular sciences. vol 18. issue 8. 2018-04-17. PMID:28758944. |
the interaction of the endocannabinoid and kynurenine system has been demonstrated to be therapeutically relevant in a number of pathological conditions, such as cannabis addiction, psychosis, schizophrenia and epilepsy. |
2018-04-17 |
2023-08-13 |
Not clear |
| Marc Fakhour. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia. Molecular neurobiology. vol 54. issue 1. 2018-02-08. PMID:26768595. |
role of the endocannabinoid system in the pathophysiology of schizophrenia. |
2018-02-08 |
2023-08-13 |
human |
| Sharon L Hollins, Katerina Zavitsanou, Frederick Rohan Walker, Murray J Cairn. Alteration of transcriptional networks in the entorhinal cortex after maternal immune activation and adolescent cannabinoid exposure. Brain, behavior, and immunity. vol 56. 2018-01-04. PMID:26923065. |
maternal immune activation (mia) and adolescent cannabinoid exposure (ace) have both been identified as major environmental risk factors for schizophrenia. |
2018-01-04 |
2023-08-13 |
rat |
| Kayla A Chase, Benjamin Feiner, Cherise Rosen, David P Gavin, Rajiv P Sharm. Characterization of peripheral cannabinoid receptor expression and clinical correlates in schizophrenia. Psychiatry research. vol 245. 2017-11-28. PMID:27591408. |
these results continue to support dysregulation of particular aspects of the endocannabinoid signaling system in participants with schizophrenia selected for the self-reported absence of marijuana abuse/dependence. |
2017-11-28 |
2023-08-13 |
human |
| Salvina Maria de Campos-Carli, Marcio Sobreira Araújo, Amanda Cardoso de Oliveira Silveira, Vitor Bortolo de Rezende, Natalia Pessoa Rocha, Rodrigo Ferretjans, Rafael Ribeiro-Santos, Andrea Teixeira-Carvalho, Olindo Assis Martins-Filho, Michael Berk, João Vinícius Salgado, Antonio Lucio Teixeir. Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms. Journal of psychiatric research. vol 87. 2017-09-19. PMID:28011441. |
cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: evidence for defective immunomodulatory mechanisms. |
2017-09-19 |
2023-08-13 |
human |
| Salvina Maria de Campos-Carli, Marcio Sobreira Araújo, Amanda Cardoso de Oliveira Silveira, Vitor Bortolo de Rezende, Natalia Pessoa Rocha, Rodrigo Ferretjans, Rafael Ribeiro-Santos, Andrea Teixeira-Carvalho, Olindo Assis Martins-Filho, Michael Berk, João Vinícius Salgado, Antonio Lucio Teixeir. Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms. Journal of psychiatric research. vol 87. 2017-09-19. PMID:28011441. |
to evaluate cannabinoid receptors (cbrs) expression on peripheral immune cells, i.e., blood monocytes, neutrophils, lymphocytes, and nk cells, and their relationship to a wide range of serum cytokine levels in subjects with schizophrenia and controls. |
2017-09-19 |
2023-08-13 |
human |
| Eduardo S Gouvêa, Airton F Santos, Vanessa K Ota, Vinicius Mrad, Ary Gadelha, Rodrigo A Bressan, Quirino Cordeiro, Sintia I Belanger. The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 39. issue 2. 2017-09-14. PMID:28099629. |
we aimed to perform a systematic review of association studies between schizophrenia (and its subphenotypes) and polymorphisms in the cnr1 gene, which encodes cannabinoid receptors classically implicated in schizophrenia pathophysiology, as well as to present unpublished results of an association study in a brazilian population. |
2017-09-14 |
2023-08-13 |
Not clear |
| Marc Fakhour. Could cannabidiol be used as an alternative to antipsychotics? Journal of psychiatric research. vol 80. 2017-09-08. PMID:27267317. |
recently, the endocannabinoid system (ecs) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. |
2017-09-08 |
2023-08-13 |
Not clear |
| David J Clarke, Jordyn Stuart, Iain S McGregor, Jonathon C Arnol. Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 72. 2017-08-30. PMID:27521758. |
endocannabinoid dysregulation in cognitive and stress-related brain regions in the nrg1 mouse model of schizophrenia. |
2017-08-30 |
2023-08-13 |
mouse |
| David J Clarke, Jordyn Stuart, Iain S McGregor, Jonathon C Arnol. Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 72. 2017-08-30. PMID:27521758. |
the endocannabinoid system is dysregulated in schizophrenia. |
2017-08-30 |
2023-08-13 |
mouse |
| Edina Szűcs, Szabolcs Dvorácskó, Csaba Tömböly, Alexandra Büki, Gabriella Kékesi, Gyöngyi Horváth, Sándor Benyh. Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia. Neuroscience letters. vol 633. 2017-07-27. PMID:27639959. |
decreased cb receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia. |
2017-07-27 |
2023-08-13 |
rat |
| Mohini Ranganathan, Jose Cortes-Briones, Rajiv Radhakrishnan, Halle Thurnauer, Beata Planeta, Patrick Skosnik, Hong Gao, David Labaree, Alexander Neumeister, Brian Pittman, Toral Surti, Yiyun Huang, Richard E Carson, Deepak Cyril D'Souz. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological psychiatry. vol 79. issue 12. 2017-07-19. PMID:26432420. |
several lines of evidence suggest the presence of abnormalities in the endocannabinoid (ecb) system in schizophrenia (scz). |
2017-07-19 |
2023-08-13 |
Not clear |